Solifenacin succinate
Keep this leaflet, you may need to read it again.
In case of any doubts, consult a doctor or pharmacist.
This medicine has been prescribed to you by a doctor. Do not pass it on to others. The medicine may harm them, even if their symptoms are the same.
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. See section 4.
Table of contents of the leaflet:
The active substance of Vesoligo belongs to a group of cholinolytic medicines. These medicines reduce the activity of an overactive urinary bladder. The action of the medicine increases the amount of urine held in the bladder, resulting in longer intervals between visits to the toilet.
Vesoligo is used to treat symptoms of an overactive bladder. These symptoms include: urgent urination, i.e. episodes of sudden, urgent need to urinate, frequent urination and incontinence, related to the fact that the patient did not have time to use the toilet.
When not to take Vesoligo:
Before starting treatment with Vesoligo, tell your doctor if any of the above situations apply or have occurred in the past.
Before starting to take Vesoligo, discuss it with your doctor or pharmacist:
Before starting treatment with Vesoligo, tell your doctor if any of the above situations apply or have occurred in the past.
Before starting treatment with Vesoligo, the doctor will assess whether there are other causes of frequent urination (e.g. heart failure - insufficient strength of the heart muscle to pump blood - or kidney disease). If a urinary tract infection occurs, the doctor will prescribe an antibiotic (an antibacterial medicine, acting on specific bacteria).
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take.
It is especially important to inform your doctor if you are taking:
p. 2
Vesoligo can be taken during meals or independently of meals.
Vesoligo should not be used during pregnancy, unless it is absolutely necessary.
Vesoligo should not be used during breastfeeding, as solifenacin passes into breast milk.
Before taking any medicine, consult a doctor or pharmacist.
Vesoligo may cause blurred vision, and less often drowsiness and fatigue.
If such side effects occur, do not drive or operate any machinery.
Vesoligo contains lactose. The medicine should not be used in patients with rare hereditary galactose intolerance, lactase deficiency (Lapp type) or glucose-galactose malabsorption syndrome.
Vesoligo should always be taken according to the doctor's recommendations.
In case of doubts, consult a doctor or pharmacist.
Swallow the tablet whole, with a drink of water.
The medicine can be taken during meals or independently of meals, depending on the patient's preferences.
Do not crush the tablets.
Usually, a dose of 5 mg per day is used, unless the doctor recommends a dose of 10 mg per day.
In case of taking too many Vesoligo tablets or if a child accidentally swallows the medicine, consult a doctor or pharmacist immediately.
Symptoms of overdose may include: headache, dry mouth, dizziness, drowsiness and vision disorders, hallucinations, excessive excitement, seizures (convulsions), breathing difficulties, rapid heartbeat (tachycardia), urinary retention and dilated pupils.
In case of missing a dose, take the next dose as soon as possible, unless it is close to the time of the next dose. Do not take the medicine more often than once a day. In case of doubts, consult a doctor or pharmacist.
In case of stopping treatment with Vesoligo, the symptoms of an overactive bladder may return or worsen. Stopping treatment should always be consulted with a doctor.
In case of any further doubts regarding the use of this medicine, consult a doctor or pharmacist.
Like all medicines, Vesoligo can cause side effects, although not everybody gets them.
If you experience an allergic reaction or a severe skin reaction (e.g. blistering and peeling of the skin), tell your doctor or nurse immediately.
In some patients taking solifenacin succinate (Vesoligo), angioedema (a form of allergic skin reaction that causes swelling of the tissue just beneath the skin surface) with swelling of the airways (difficulty breathing) has been reported. If you experience angioedema, stop taking solifenacin succinate (Vesoligo) and start appropriate treatment and/or take appropriate measures.
Vesoligo may cause other side effects, including:
Very common (may affect more than 1 in 10 people) side effects include:
Common (may affect up to 1 in 10 people) side effects include:
p. 4
Uncommon (may affect up to 1 in 100 people) side effects include:
Rare (may affect up to 1 in 1000 people) side effects include:
Frequency not known (frequency cannot be estimated from the available data)
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist, or nurse.
Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Jerozolimskie Avenue 181C,
02-222 Warsaw,
tel.: 22 49-21-301,
fax: 22 49-21-309,
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.
Keep the medicine out of sight and reach of children.
There are no special precautions for storage.
Do not use this medicine after the expiry date (EXP) stated on the carton/blister. The expiry date refers to the last day of the month.
Do not use this medicine if the packaging is damaged or visible signs of deterioration are observed.
p. 5
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of Vesoligo is solifenacin succinate (Solifenacini succinas) in an amount of 5 mg or 10 mg
The other ingredients are:
tablet core: Lactose monohydrate, Corn starch, Hypromellose 6cPs, Magnesium stearate,
tablet coating: Hypromellose 6cPs, Macrogol 8000, Talc, Titanium dioxide (E171),
Iron oxide yellow (E172) for 5mg dose,
Iron oxide red (E172) for 10mg dose.
Vesoligo 5 mg coated tablets are round, light yellow, marked with the number "390" on one side of the tablet.
Vesoligo 10 mg coated tablets are round, light pink, marked with the number "391" on one side of the tablet.
The tablets are packaged in PVC/PVDC/Aluminum blisters and cardboard boxes containing: 10, 20, 30 or 90 coated tablets.
Not all pack sizes may be marketed.
Marketing authorization holder:
LEK-AM Pharmaceutical Company Ltd.
Ostrzykowizna 14 A
05-170 Zakroczym
Poland
Tel.: +48 22 785 27 60
Fax: +48 22 785 27 60 ext. 106
Manufacturer:
Zentiva S.A.
Theodor Pallady Boulevard no. 50, sector 3
032266 Bucharest
Romania
Date of last revision of the leaflet:
p. 6
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.